COMPANY OVERVIEW

Cancer is the number one killer of people in the prime of life. The medical community is desperately searching for better ways to detect, diagnose, and treat cancer. Traditional tests such as the pap test, mammography, PSA, colposcopy and countless other "standard-of-care" tests do not actually test for cancer or its precursors. Instead, they identify abnormalities that are only associated with the possibility of cancer. Thus, many cancers are diagnosed at a late stage where the chances of survival are reduced. Or for many others, individuals are subjected to countless tests and invasive procedures only to find that their abnormal test results are due to an unrelated, benign condition.

It has been long understood that the improvement in cancer testing will be based on the development of highly sensitive and specific molecular diagnostic methods. In the words of world renowned Johns Hopkins University researcher, Dr. Bert Vogelstein, "virtually every cancer has an abnormal chromosome complement". Identifying these genetic abnormalities using molecular diagnostic testing is the premise on which NeoDiagnostix was founded. We have a team with highly specialized experience and skills in the area of Fluorescent In Situ Hybridization (FISH) and molecular diagnostic techniques. We use these technologies to see if DNA damage has occurred to critical genes that affect the potential for cancer development. Unlike other molecular technologies, FISH enables us not only to detect these rare cell events at the genetic level but to view them in their cellular "context".

Our flagship product, the Cervical DNA Dtex® test was launched in 2007 for the early detection of chromosomal changes that signal the development of cervical cancer. We are also developing molecular diagnostic assays for breast, bladder and oral cancer.